Make earnings with no risk
Automated AI-driven system makes the trades, you earn the money
Join now
News

Wall Street Speculates on Match Group’s Acquisition of Bumble

0

Wall Street is abuzz with speculation about the potential integration of Bumble, a rival dating app, into the Match Group’s portfolio. According to Forbes, Match Group has been in talks with Bumble regarding a possible acquisition for a staggering $1 billion. Notably, Bumble had previously rejected a $450 million offer from Tinder earlier this year.

While both Tinder and Bumble are dating apps that allow users to swipe left or right to express interest in potential matches, Bumble distinguishes itself by requiring women to initiate conversations.

Analyst Sam Kemp from Piper Jaffray believes that an acquisition of Bumble would be a “financially and strategically sensible” move for Match Group, despite the higher price tag. He highlights that Bumble, much like Tinder, benefits from advantageous user acquisition dynamics, which rely less on marketing expenditures. Furthermore, he suggests that encouraging more users to sign up for the paid version of the service would incur minimal costs.

The potential integration between these two services presents additional opportunities for mutual growth. Kemp suggests that Bumble’s user base is likely comprised of a higher proportion of paying members compared to Tinder. By leveraging Bumble’s insights, Tinder could accelerate the promotion of its paid features. Conversely, Tinder could share its advertising technology with Bumble, enhancing the latter’s revenue potential.

It is worth noting that Bumble and Tinder share a complex history. Bumble was developed by a co-founder of Tinder, who subsequently left the company and filed lawsuits alleging sexual harassment and sex discrimination. The parties reportedly settled for $1 million.

In conclusion, Wall Street eagerly awaits further developments surrounding Match Group’s potential acquisition of Bumble.

fxcoach

Liminal BioSciences Inc. to Go Private

Previous article

Regeneron Pharmaceuticals Announces FDA Approval for Higher-Dose Eylea Formulation

Next article

You may also like

Comments

Leave a reply

Your email address will not be published.

More in News